Prevalence of carbapenemase genes among multidrug-resistant Pseudomonas aeruginosa isolates from tertiary care centers in Southern Thailand

References

1. 1.↵
   1. Cerceo E,
   2. Deitelzweig SB,
   3. Sherman BM,
   4. Amin AN.

   Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist 2016; 22: 412–431.

   OpenUrlCrossRefPubMed
2. 2.↵
   Centers for Disease Control and Prevention. Pseudomonas aeruginosa in healthcare settings. [Updated 2020; accessed 2021 Nov 16]. Available from: https://www.cdc.gov/hai/organisms/pseudomonas.html
3. 3.↵
   National Antimicrobial Resistance Surveillance Thailand. Antibiotrend 2000-2013. [Updated 2021; accessed 2021 Oct 11]. Available from: http://narst.dmsc.moph.go.th/antibiotrend.pdf
4. 4.↵
   1. Campana S,
   2. Taccetti G,
   3. Ravenni N,
   4. Masi I,
   5. Audino S,
   6. Sisi B, et al.

   Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros 2004; 3: 159–163.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Pasteran F,
   2. Veliz O,
   3. Rapoport M,
   4. Guerriero L,
   5. Corso A.

   Sensitive and specific modified Hodge test for KPC and metallo-beta- lactamase detection in Pseudomonas aeruginosa by use of a novel indicator strain, Klebsiella pneumoniae ATCC 700603. J Clin Microbiol 2011; 49: 4301–4303.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Woodford N.

   Rapid characterization of β-lactamases by multiplex PCR. MIMB 2010; 642: 181–192.

   OpenUrl
7. 7.↵
   Division of Microbiology, Faculty of Medicine, Prince of Songkla University. Percentage of suscepible bacteria Songkanagarind Hospital Jan-Dec2018. (Updated 2019; accessed 2022 June 14). Available from: https://scholar.google.com/scholar_lookup?title=Molecular%20biology%20-%20PFGE%20analysis%20of%20chromosomal%20restriction%20fragments&publication_year=1992&author=Pfaller%2CMA&author=Hollis%2CRJ&author=Sader%2CHS
8. 8.↵
   1. Nordmann P,
   2. Naas T,
   3. Poirel L.

   Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791–1798.

   OpenUrlCrossRefPubMed
9. 9.↵
   Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M07. 10th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2015.
10. 10.↵
    Wayne P. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20-U. USA: CLSI; 2010. USA2010.
11. 11.↵
    1. Harrington SM,
    2. Stock F,
    3. Kominski AL,
    4. Campbell JD,
    5. Hormazabal JC,
    6. Livio S, et al.

    Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semiautomated repetitive-element PCR and pulsed-field gel electrophoresis. J Clin Microbiol 2007; 45: 707–714.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Magiorakos AP,
    2. Srinivasan A,
    3. Carey RB,
    4. Carmeli Y,
    5. Falagas ME,
    6. Giske CG, et al.

    Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268–281.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Gupta V.

    Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opin Investig Drugs 2008; 17: 131–143.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Poirel L,
    2. Walsh TR,
    3. Cuvillier V,
    4. Nordmann P.

    Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 2011; 70: 119–123.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Pfaller M,
    2. Hollis R,
    3. Sader H.

    Molecular biology-PFGE analysis of chromosomal restriction fragments. Clinical Microbiology Procedures Handbook. 1992; 10: 1–10.

    OpenUrl
16. 16.↵
    1. Seifert H,
    2. Dolzani L,
    3. Bressan R,
    4. van der Reijden T,
    5. van Strijen B,
    6. Stefanik D, et al.

    Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J Clin Microbiol 2005; 43: 4328–4335.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Tenover FC,
    2. Arbeit RD,
    3. Goering RV,
    4. Mickelsen PA,
    5. Murray BE,
    6. Persing DH, et al.

    Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33: 2233–2239.

    OpenUrlFREE Full Text
18. 18.↵
    1. Matos ECO,
    2. Andriolo RB,
    3. Rodrigues YC,
    4. Lima PDL,
    5. Carneiro ICDRS,
    6. Lima KVB.

    Mortality in patients with multidrug-resistant Pseudomonas aeruginosa infections: a meta-analysis. Rev Soc Bras Med Trop 2018; 51: 415–420.

    OpenUrlCrossRef
19. 19.↵
    1. Swathirajan CR,
    2. Rameshkumar MR,
    3. Solomon SS,
    4. Vignesh R,
    5. Balakrishnan P.

    Changing drug resistance profile in Pseudomonas aeruginosa infection among HIV patients from 2010-2017: a retrospective study. J Glob Antimicrob Resist 2019; 16: 274–277.

    OpenUrl
20. 20.↵
    1. Moore JE,
    2. Mastoridis P.

    Clinical implications of Pseudomonas aeruginosa location in the lungs of patients with cystic fibrosis. J Clin Pharm Ther 2017; 42: 259–267.

    OpenUrl
21. 21.↵
    1. Yayan J,
    2. Ghebremedhin B,
    3. Rasche K.

    Antibiotic resistance of Pseudomonas aeruginosa in pneumonia at a single university hospital center in Germany over a 10-year period. PLoS One 2015; 10: e0139836.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Bhatt P,
    2. Rathi KR,
    3. Hazra S,
    4. Sharma A,
    5. Shete V.

    Prevalence of multidrug resistant Pseudomonas aeruginosa infection in burn patients at a tertiary care centre. Indian J Burns 2015; 23: 56–59.

    OpenUrl
23. 23.↵
    1. Ocampo W,
    2. Geransar R,
    3. Clayden N,
    4. Jones J,
    5. de Grood J,
    6. Joffe M, et al.

    Environmental scan of infection prevention and control practices for containment of hospital-acquired infectious disease outbreaks in acute care hospital settings across Canada. Am J Infect Control 2017; 45: 1116–1126.

    OpenUrlPubMed
24. 24.↵
    1. Sader HS,
    2. Flamm RK,
    3. Carvalhaes CG,
    4. Castanheira M.

    Antimicrobial susceptibility of Pseudomonas aeruginosa to ceftazidime-avibactam, ceftolozane-tazobactam, piperacillin-tazobactam, and meropenem stratified by US Census Divisions: results from the 2017 INFORM program. Antimicrob Agents Chemother 2018; 62: e01518–e01587.

    OpenUrl
25. 25.↵
    1. Sader HS,
    2. Huband MD,
    3. Castanheira M,
    4. Flamm RK.

    Pseudomonas aeruginosa antimicrobial susceptibility results from 4 years (2012-2015) of the International Network for Optimal Resistance Monitoring Program in the United States. Antimicrob Agents Chemother 2017; 61: e02252–e02216.

    OpenUrl
26. 26.↵
    1. Ko WC,
    2. Stone GG.

    In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017). Ann Clin Microbiol Antimicrob 2020; 19: 14.

    OpenUrl
27. 27.↵
    1. Thunyaharn S.

    The genotypic detection of blaVIM-2 among clinical carbapenem resistant Pseudomonas aeruginosa isolates from Phramongkutklao hospital Thailand. Royal Thai Army Med J. 2021; 74: 173–178.

    OpenUrl
28. 28.↵
    1. Murugan N,
    2. Malathi J,
    3. Therese KL,
    4. Madhavan HN.

    Application of 6 multiplex PCR’s among 200 clinical isolates of Pseudomonas aeruginosa for the detection of 20 drug resistance encoding genes. Kaohsiung J Med Sci 2018; 34: 79–88.

    OpenUrl